The inhibition of tube formation in a collagen-fibrinogen, three-dimensional gel by cleaved kininogen (HKa) and HK domain 5 (D5) is dependent on Src family kinases

Experimental Cell Research

Volumn 314, Issue 4, 2008, Pages 774-788

  Liu, Yuchuan ^a   Sainz, Irma M ^a   Wu, Yi ^a   Pixley, Robin ^a   Espinola, Ricardo G ^a   Hassan, Sarmina ^a   Khan, Mohammad M ^a   Colman, Robert W ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; C terminal Srk kinases; Integrin; Kininogen; Src family kinase; uPAR; v 3

Indexed keywords

COLLAGEN FIBRIL; KININOGEN; STEROID RECEPTOR COACTIVATOR 1;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NEOVASCULARIZATION (PATHOLOGY); PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

EID: 38949121713     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2007.10.008     Document Type: Article

References (55)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease [Review] [72 refs]. Nat. Med. 1 (1995) 27-31
2. Fernandez P.M., Patierno S.R., and Rickles F.R. Tissue factor and fibrin in tumor angiogenesis. Semin. Thromb. Hemost. 30 (2004) 31-44
3. Ruf W., and Mueller B.M. Thrombin generation and the pathogenesis of cancer. Semin. Thromb. Hemost. 32 Suppl 1 (2006) 61-68
4. Nagy J.A., Brown L.F., Senger D.R., Lanir N., Van de Water L., Dvorak A.M., and Dvorak H.F. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim. Biophys. Acta 948 (1989) 305-326
5. Tsopanoglou N.E., and Maragoudakis M.E. Role of thrombin in angiogenesis and tumor progression. Semin. Thromb. Hemost. 30 (2004) 63-69
6. Colman R.W. Biologic activities of the contact factors in vivo-potentiation of hypotension, inflammation, and fibrinolysis, and inhibition of cell adhesion, angiogenesis and thrombosis. Thromb. Haemost. 82 (1999) 1568-1577
7. Colman R.W., and Schmaier A.H. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood 90 (1997) 3819-3843
8. Mori K., and Nagasawa S. Studies on human high molecular weight (HMW) kininogen. II. Structural change of HMW kininogen by the action of human plasma kallikrein. J. Biochem. (Tokyo) 89 (1981) 1465-1473
9. Colman R.W., Jameson B.A., Lin Y., Johnson D., and Mousa S.A. Domain 5 of high molecular weight kininogen (kininostatin) down-regulates endothelial cell proliferation and migration and inhibits angiogenesis. Blood 95 (2000) 543-550
10. Guo Y.L., Wang S., and Colman R.W. Kininostatin, an angiogenic inhibitor, inhibits proliferation and induces apoptosis of human endothelial cells. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1427-1433
11. Guo Y.L., Wang S., Cao D.J., and Colman R.W. Apoptotic effect of cleaved high molecular weight kininogen is regulated by extracellular matrix proteins. J. Cell. Biochem. 89 (2003) 622-632
12. Im E., and Kazlauskas A. Src family kinases promote vessel stability by antagonizing the Rho/ROCK pathway. J. Biol. Chem. 282 (2007) 29122-29129
13. Werdich X.Q., and Penn J.S. Specific involvement of SRC family kinase activation in the pathogenesis of retinal neovascularization. Investig. Ophthalmol. Vis. Sci. 47 (2006) 5047-5056
14. Donnini S., Monti M., Castagnini C., Solito R., Botta M., Schenone S., Giachetti A., and Ziche M. Pyrazolo-pyrimidine-derived c-Src inhibitor reduces angiogenesis and survival of squamous carcinoma cells by suppressing vascular endothelial growth factor production and signaling. Int. J. Cancer 120 (2007) 995-1004
15. Arias-Salgado E.G., Lizano S., Sarkar S., Brugge J.S., Ginsberg M.H., and Shattil S.J. Src kinase activation by direct interaction with the integrin beta cytoplasmic domain. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 13298-13302
16. Brooks P.C., Stromblad S., Klemke R., Visscher D., Sarkar F.H., and Cheresh D.A. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J. Clin. Invest. 96 (1995) 1815-1822
17. Wei Y., Czekay R.P., Robillard L., Kugler M.C., Zhang F., Kim K.K., Xiong J.P., Humphries M.J., and Chapman H.A. Regulation of {alpha}5{beta}1 integrin conformation and function by urokinase receptor binding. J. Cell Biol. 168 (2005) 501-511
18. Wei Y., Eble J.A., Wang Z., Kreidberg J.A., and Chapman H.A. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol. Biol. Cell 12 (2001) 2975-2986
19. Davis G.E., and Camarillo C.W. An alpha 2 beta 1 integrin-dependent pinocytic mechanism involving intracellular vacuole formation and coalescence regulates capillary lumen and tube formation in three-dimensional collagen matrix. Exp. Cell Res. 224 (1996) 39-51
20. Yang B., Cao D.J., Sainz I., Colman R.W., and Guo Y.L. Different roles of ERK and p38 MAP kinases during tube formation from endothelial cells cultured in 3-dimensional collagen matrices. J. Cell. Physiol. 200 (2004) 360-369
21. Liu Y., Pelekanakis K., and Woolkalis M.J. Thrombin and tumor necrosis factor alpha synergistically stimulate tissue factor expression in human endothelial cells: regulation through c-Fos and c-Jun. J. Biol. Chem. 279 (2004) 36142-36147
22. Zhang L., Zalewski A., Liu Y., Mazurek T., Cowan S., Martin J.L., Hofmann S.M., Vlassara H., and Shi Y. Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation 108 (2003) 472-478
23. Yang S., Graham J., Kahn J.W., Schwartz E.A., and Gerritsen M.E. Functional roles for PECAM-1 (CD31) and VE-cadherin (CD144) in tube assembly and lumen formation in three-dimensional collagen gels. Am. J. Pathol. 155 (1999) 887-895
24. Liu Y., and Senger D.R. Matrix-specific activation of Src and Rho initiates capillary morphogenesis of endothelial cells. FASEB J. 18 (2004) 457-468
25. Ischenko I., Guba M., Yezhelyev M., Papyan A., Schmid G., Green T., Fennell M., Jauch K.W., and Bruns C.J. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis 10 (2007) 167-182
26. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., Pollok B.A., and Connelly P.A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation. J. Biol. Chem. 271 (1996) 695-701
27. Amin D.N., Hida K., Bielenberg D.R., and Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res. 66 (2006) 2173-2180
28. Boggon T.J., and Eck M.J. Structure and regulation of Src family kinases. Oncogene 23 (2004) 7918-7927
29. Schieven G.L., Kallestad J.C., Brown T.J., Ledbetter J.A., and Linsley P.S. Oncostatin M induces tyrosine phosphorylation in endothelial cells and activation of p62yes tyrosine kinase. J. Immunol. 149 (1992) 1676-1682
30. Kannan S., Audet A., Knittel J., Mullegama S., Gao G.F., and Wu M. Src kinase Lyn is crucial for Pseudomonas aeruginosa internalization into lung cells. Eur. J. Immunol. 36 (2006) 1739-1752
31. Roskoski Jr. R. Src kinase regulation by phosphorylation and dephosphorylation. Biochem. Biophys. Res. Commun. 331 (2005) 1-14
32. Duan L.J., Imamoto A., and Fong G.H. Dual roles of the C-terminal Src kinase (Csk) during developmental vascularization. Blood 103 (2004) 1370-1372
33. Nada S., Yagi T., Takeda H., Tokunaga T., Nakagawa H., Ikawa Y., Okada M., and Aizawa S. Constitutive activation of Src family kinases in mouse embryos that lack Csk. Cell 73 (1993) 1125-1135
34. Herrick S., Blanc-Brude O., Gray A., and Laurent G. Fibrinogen. Int. J. Biochem. Cell Biol. 31 (1999) 741-746
35. White D.J., Puranen S., Johnson M.S., and Heino J. The collagen receptor subfamily of the integrins. Int. J. Biochem. Cell Biol. 36 (2004) 1405-1410
36. Wei Y., Tang C.H., Kim Y., Robillard L., Zhang F., Kugler M.C., and Chapman H.A. Urokinase receptors are required for {alpha}5beta1 integrin-mediated signaling in tumor cells. J. Biol. Chem. 282 (2007) 3929-3939
37. Cao D.J., Guo Y.L., and Colman R.W. Urokinase-type plasminogen activator receptor is involved in mediating the apoptotic effect of cleaved high molecular weight kininogen in human endothelial cells. Circ. Res. 94 (2004) 1227-1234
38. Mahdi F., Shariat-Madar Z., Kuo A., Carinato M., Cines D.B., and Schmaier A.H. Mapping the interaction between high molecular weight kininogen and the urokinase plasminogen activator receptor. J. Biol. Chem. 279 (2004) 16621-16628
39. Hasan A.A.K., Cines D.B., Herwald H., Schmaier A.H., and Muller-Esterl W. Mapping the cell binding site on high molecular weight kininogen domain 5. J. Biol. Chem. 270 (1995) 19256-19261
40. Klint P., Kanda S., Kloog Y., and Claesson-Welsh L. Contribution of Src and Ras pathways in FGF-2 induced endothelial cell differentiation. Oncogene 18 (1999) 3354-3364
41. Di Fulvio M., Frondorf K., Henkels K.M., Lehman N., and Gomez-Cambronero J. The Grb2/PLD2 interaction is essential for lipase activity, intracellular localization and signaling in response to EGF. J. Mol. Biol. 367 (2007) 814-824
42. Labrecque L., Nyalendo C., Langlois S., Durocher Y., Roghi C., Murphy G., Gingras D., and Beliveau R. Src-mediated tyrosine phosphorylation of caveolin-1 induces its association with membrane type 1 matrix metalloproteinase. J. Biol. Chem. 279 (2004) 52132-52140
43. Kanda S., Kanetake H., and Miyata Y. HGF-induced capillary morphogenesis of endothelial cells is regulated by Src. Biochem. Biophys. Res. Commun. 344 (2006) 617-622
44. Werdich X.Q., and Penn J.S. Src, Fyn and Yes play differential roles in VEGF-mediated endothelial cell events. Angiogenesis 8 (2005) 315-326
45. Baumeister U., Funke R., Ebnet K., Vorschmitt H., Koch S., and Vestweber D. Association of Csk to VE-cadherin and inhibition of cell proliferation. EMBO J. 24 (2005) 1686-1695
46. Joseph K., Ghebrehiwet B., and Kaplan A.P. Cytokeratin 1 and gC1qR mediate high molecular weight kininogen binding to endothelial cells. Clin. Immunol. 92 (1999) 246-255
47. Zhang J.C., Qi X., Juarez J., Plunkett M., Donate F., Sakthivel R., Mazar A.P., and McCrae K.R. Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides. Can. J. Physiol. Pharm. 80 (2002) 85-90
48. Mahdi F., Shariat-Madar Z., Todd III R.F., Figueroa C.D., and Schmaier A.H. Expression and colocalization of cytokeratin 1 and urokinase plasminogen activator receptor on endothelial cells. Blood 97 (2001) 2342-2350
49. Colman R.W., Pixley R.A., Najamunnisa S., Yan W., Wang J., Mazar A., and McCrae K.R. Binding of high molecular weight kininogen to human endothelial cells is mediated via a site within domains 2 and 3 of the urokinase receptor. J. Clin. Invest. 100 (1997) 1481-1487
50. Khan M.M., Bradford H.N., Isordia-Salas I., Liu Y., Wu Y., Espinola R.G., Ghebrehiwet B., and Colman R.W. High-molecular-weight kininogen fragments stimulate the secretion of cytokines and chemokines through uPAR, Mac-1, and gC1qR in monocytes. Arterioscler. Thromb. Vasc. Biol. (2006) 2260-2266
51. Tarui T., Akakura N., Majumdar M., Andronicos N., Takagi J., Mazar A.P., Bdeir K., Kuo A., Yarovoi S.V., Cines D.B., and Takada Y. Direct interaction of the kringle domain of urokinase-type plasminogen activator (uPA) and integrin alpha v beta 3 induces signal transduction and enhances plasminogen activation. Thromb. Haemost. 95 (2006) 524-534
52. Brooks P.C., Clark R.A., and Cheresh D.A. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264 (1994) 569-571
53. Reynolds L.E., Wyder L., Lively J.C., Taverna D., Robinson S.D., Huang X., Sheppard D., Hynes R.O., and Hodivala-Dilke K.M. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat. Med. 8 (2002) 27-34
54. Mahabeleshwar G.H., Feng W., Phillips D.R., and Byzova T.V. Integrin signaling is critical for pathological angiogenesis. J. Exp. Med. (2006) 2495-2507
55. Bhaskar V., Fox M., Breinberg D., Wong M.H., Wales P.E., Rhodes S., Dubridge R.B., and Ramakrishnan V. Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits. Invest. New Drugs (2007) 10.1007/s10637-007-9078-7